KURA · Kura Oncology
AI read · Good for KURA
The AI's read
This is an outside analyst's opinion, not a change in Kura's business. The higher target and continued bullish rating favor its shares, but the story reports no new company results.
J.P. Morgan raised its target from $30 to $32 and kept its bullish rating.
This is an outside analyst's opinion, not a change in Kura's business. The higher target and continued bullish rating favor its shares, but the story reports no new company results.
Follow Kura Oncology (KURA) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for KURA